Treatment of psoriatic arthritis (PsA) typically begins with conventional disease-modifying antirheumatic drugs (DMARDs), such as methotrexate, and progresses to more-potent biologics and/or targeted oral therapies as needed. The U.S. market for conventional DMARD-refractory PsA is crowded with multiple efficacious therapies, including six tumor necrosis factor-alpha (TNF-α) inhibitors, two interleukin (IL)-17 inhibitors, an IL-12/23 inhibitor, an IL-23 inhibitor, and two targeted oral agents (a PDE4 inhibitor and a JAK inhibitor). There were two more additions to this already exhaustive list owing to the recent approvals of AbbVie’s Skyrizi and Rinvoq (an IL-23 inhibitor and a JAK inhibitor, respectively). The advent of these newer agents will intensify the competition between targeted therapies in an already cluttered therapy market, leading to interesting patient-share dynamics.
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Markets covered: United States
Key companies: AbbVie, Amgen, Janssen, Novartis, Eli Lilly, Pfizer, Sun Pharma, UCB
Key drugs: Humira, Enbrel, Remicade, biosimilar infliximab, Cimzia, Simponi, Simponi Aria, Stelara, Cosentyx, Taltz, Orencia, Otezla, Xeljanz, Methotrexate
The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and quarterly data refreshes.